Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
Currently existing behavioral measures for motor impairments in rodent models with bilateral dopamine depletion have demonstrated to be difficult to assess due to the degree of task complexity. There is clearly a need for a behavioral test that is simplistic in design and does not require the animal to learn a specific task, in particular for mice. Here we adapted the stepping test, originally designed for assessing asymmetric motor deficits in rats (Olsson, M., Nikkhah, G., Bentlage, C., Bjorklund, A., 1995. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15, 3863-3875; Schallert, T., De Ryck, M., Whishaw, I.Q., Ramirez, V.D., Teitelbaum, P., 1979. Excessive bracing reactions and their control by atropine and l-DOPA in an animal analog of Parkinsonism. Exp. Neurol. 64, 33-43), into a mouse-friendly version for bilateral dopamine lesion induced by subacute MPTP injection. We found that MPTP-treated mice exhibit a significant and persistent reduction in the number of adjusting steps when compared to saline-treated animals. Typically, MPTP-induced stepping deficit becomes apparent by the fourth MPTP injection. The number of adjusting steps continues to decline throughout the injections, and by day 10 from the last MPTP injection, the stepping deficit observed is associated with approximately 65% TH positive cells loss in the SN. Importantly, L-DOPA administration significantly improved stepping performance in MPTP-treated mice. Thus, stepping test in mice is a reliable and simple behavioral measure for assessing forelimb akinesia induced by systemic MPTP.
Blume
Shannon R
SR
Department of Cellular and Molecular Pharmacology, Rosalind Franklin University of Medicine and Science, The Chicago Medical School, North Chicago, IL 60064, USA.
Cass
Daryn K
DK
Tseng
Kuei Y
KY
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D002452:Cell Count; D004195:Disease Models, Animal; D005552:Forelimb / Q000294:innervation / Q000503:physiopathology*; D018476:Hypokinesia / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology; D007794:Lameness, Animal / Q000175:diagnosis* / Q000503:physiopathology; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009410:Nerve Degeneration / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D009460:Neurologic Examination; D020734:Parkinsonian Disorders / Q000175:diagnosis* / Q000503:physiopathology; D011237:Predictive Value of Tests; D012680:Sensitivity and Specificity; D013378:Substantia Nigra / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology
D000978:Antiparkinson Agents; D007980:Levodopa